Keywords
Guillain–Mollaret triangle - hypertrophic olivary degeneration - magnetic resonance
imaging
Introduction
Hypertrophic olivary degeneration (HOD) is a rare occurrence in which different pathological
processes including enlargement and vacuolation of the neurons, demyelination of the
white matter, and fibrillary gliosis of the inferior olivary nucleus take place. It
mostly develops secondary to a destructive lesion in brainstem or cerebellum involving
the Guillain–Mollaret pathway. This pathway is located in a triangle-shaped anatomical
region of which the three corners are formed by inferior olivary nucleus, ipsilateral
red nucleus, and contralateral dentate nucleus [[Figure 1]]. The mostly reported destructive lesions causing HOD are stroke, trauma, tumors,
neurosurgical interventions, and gamma knife treatment of brainstem cavernoma.[[1]]
Figure 1 (A and B): (A) Illustrative and (B) schematic figures of Guillain–Mollaret triangle. Blue, red
and green colored figures represent the left inferior olivary nucleus, ipsilateral
red nucleus and contralateral dentate nucleus, respectively. The dark blue lines represent
the connections between nuclei, and the yellow line represents the central tegmental
tract
Case Report
A 62-year-old male admitted to the hospital with the complaints of intermittent clicking
in the throat, which persists during sleep, and deficiency in the eye movements. He
had a history of stroke two years prior to the admittance. On physical examination,
palatal tremor and abducens nerve palsy were recorded. The patient was then referred
to the Department of Radiology for a brain magnetic resonance imaging (MRI). MRI demonstrated
extensive areas of encephalomalacia in the posteromedial portions of the left cerebral
hemisphere, posterolateral portions of both thalami and in the left cerebral peduncle
[[Figure 2A] and [B]]. MRI also depicted a focal, ill-defined lesion involving the olivary region of
the left half of the medulla oblongata, which was hyperintense on T2-weighted and
fluid attenuation inversion recovery (FLAIR) images [[Figure 2C] and [D]]. The lesion was indistinguishable on T1-weighted images, and did not enhance following
contrast administration. No evidence of restriction of diffusion was observed on diffusion
weighted images and apparent diffusion coefficient (ADC) mapping [[Figure 3]]. The lesion was causing expansion of the brainstem [[Figure 4]]. Combining the history and clinical and imaging findings, the patient was diagnosed
as having HOD.
Figure 2 (A-D): (A) Axial and (B) coronal T2-weighted images demonstrate areas of encephalomalacia
on the posteromedial portions of the left cerebral hemisphere (open arrows) and the
left cerebral peduncle (solid arrows). (C) Axial T2-weighted and (D) FLAIR images
show an ill-defined, focal hyperintense lesion in the olivary region of the left half
of the medulla oblongata (solid arrows)
Figure 3 (A-C): (A) Axial brain MRI sections passing through the olivary region show that the lesion
does not enhance on contrast-enhanced image, and shows no restriction of diffusion
on (B) diffusion weighted image and (C) ADC mapping
Figure 4 (A-C): (A) Axial FLAIR, (B) sagittal FLAIR, and (C) coronal T2-weighted images show a focal,
oval-shaped lesion in the olivary region of the left half of the medulla oblongata,
which causes expansion of the brainstem (arrows)
Discussion
HOD, a special type of degeneration characterized by nuclear enlargement rather than
atrophy, develops weeks or months following the occurrence of a destructive lesion
within the Guillain–Mollaret pathway. It occurs as a result of the denervation of
olivary neurons by the disruption of the dentatorubral or the rubro-olivary pathways.
Denervated neurons enlarge and develop oscillations, which are then modulated by cerebellum
causing abnormal motor output in the branchial arches.[[1]] This type of degeneration is unique in which it causes hypertrophy rather than
atrophy of the nucleus. It clinically presents with symptomatic palatal tremor resulting
from the rhythmic contractions of the levator veli palatini muscle. These contractions
cause unintentional movements of the soft palate and pharynx, which continue during
sleep. Palatal tremor develops 1 month to 8 years after the occurrence of the destructive
lesion, and persists for life. According to the location of the destructive lesion,
different neurological manifestations including contralateral hemiplegia/hemihypoesthesia
or spinothalamic syndrome, ipsilateral facial palsy or kinetic cerebellar syndrome,
abducens nerve palsy, and internuclear ophthalmoplegia may accompany palatal tremor.
MRI is the method of choice in demonstrating HOD. It typically appears as an expansive
nonenhancing nodular lesion, which shows increased signal intensity on T2-weighted
and FLAIR images.[[2]] The signal increase in the olive is visible nearly one month after the onset of
palatal tremor, whereas the enlargement of the nucleus takes approximately six months
to appear.[[1]] In the cases with cerebellar lesions, HOD appears in the contralateral side, whereas
it appears in the ipsilateral side in the cases with central tegmental tract lesions.[[3]] The enlargement of the olivary nucleus resolves in about three to four years; however,
the hyperintensity persists for life.[[1]] In some rare cases, also the increased signal of the nucleus may resolve.[[4]]
The identification of HOD on MRI is of great importance as its MRI appearance is very
similar to those of more severe pathologies including tumors, infarction, demyelinating
lesions, and infections. The lack of contrast-enhancement of HOD helps differentiating
it from malignant tumors and inflammation. And nuclear enlargement is not a usual
finding in cases with demyelinating lesions and chronic infarcts. Diffusion tensor
imaging and MR fiber tractography are shown to be useful in demonstrating the disruption
of the Guillain–Mollaret pathway in the cases with unclear conventional MRI findings.[[5],[6]]
Declaration of patient consent
The authors certify that they have obtained all appropriate patient consent forms.
In the form the patient(s) has/have given his/her/their consent for his/her/their
images and other clinical information to be reported in the journal. The patients
understand that their names and initials will not be published and due efforts will
be made to conceal their identity, but anonymity cannot be guaranteed.
